Feature | November 07, 2013

FDA Approves Medtronic Software for Use With Non-Medtronic Leads to Detect Defibrillator Lead Issues

LIA software proven to detect lead failures more frequently than impedance alone on Riata, Durata and Endotak Leads

November 7, 2013 — Medtronic Inc. announced U.S. Food and Drug Administration (FDA) approval of its Lead Integrity Alert (LIA) software for use with non-Medtronic leads. Proprietary and exclusive software that resides in Medtronic defibrillators, LIA is now approved to report performance issues on Durata and Riata defibrillator leads (St. Jude Medical) and Endotak (Boston Scientific) defibrillator leads when connected to a Medtronic device.
 
Originally approved by the FDA in 2008 for use with Medtronic defibrillators and leads, LIA has displayed the ability to detect pace/sense lead issues in non-Medtronic leads at a greater rate than standard impedance monitoring alone, according to an analysis recently published in Circulation: Arrhythmia and Electrophysiology.  For Durata and Riata leads (St. Jude Medical), LIA software detected pace/sense circuit issues approximately six times more frequently than with impedance monitoring.  The software detected pace/sense circuit issues more frequently for Endotak (Boston Scientific) leads as well.
 
"This approval affirms the applicability of Medtronic's LIA-enabled defibrillators in detecting lead issues in those leads developed by other manufacturers," said Kenneth Ellenbogen, M.D., Kontos Professor of Cardiology, Virginia Commonwealth University (VCU) School of Medicine and Medical College, Virginia Hospital.
 
In the United States, approximately 12,000 Medtronic LIA-enabled defibrillators (implantable cardioverter defibrillators (ICDs) and cardiac resynchronizationtherapy devices (CRT-Ds)) are connected to non-Medtronic leads, as identified and monitored remotely via the Medtronic CareLink Network. This includes approximately 5,100 Endotak leads, 6,100 Riata/Durata leads from St. Jude Medical and nearly 500 leads from other manufacturers, including Biotronik. An external panel of physicians who had access to device-stored electrograms and the clinical interpretation of the treating physician adjudicated non-Medtronic lead issues identified by LIA.
 
"We've seen the effectiveness of the LIA software with Medtronic devices and leads these past four years, and we know it can have an impact beyond our leads," said Marshall Stanton, M.D., vice president, Medtronic. "LIA detects lead failures better than impedance alone and this approval provides implanting physicians with performance information on this advanced decision-making tool to benefit the health and well-being of their patients."
 
LIA is included in the SmartShock suite of algorithms that yields the lowest occurrence rate of inappropriate shocks for any defibrillator in the industry. [i] [ii]
 
For more information: www.medtronic.com
 
References:
[i] Schloss EJ, et al. PainFree SST Trial Primary Results:  Low Shock Rates in Patients with Dual and Triple Chamber ICDs Using Novel Detection Algorithms. Heart Rhythm. 2013;10(50):S64.
[ii] Schloss E, et al. PainFree SmartShock technology: trial primary results: inappropriate shock rates in patients with single chamber ICD's using a novel suite of detection algorithms. EHRA Europace 2013 Late Breaking Trial session 1. 
 

Related Content

OPTILINK HF trial, ICDs, implantable cardioverter defibrillators, pulmonary congestion, automated alerts, ESC 2015
Feature | Heart Failure| September 01, 2015
Automated alerts for excess fluid accumulation in the lungs did not improve outcomes for heart failure patients with...
News | Atrial Fibrillation| September 01, 2015
The first-ever two-year outcomes from the Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF...
Medtronic, sudden cardiac death, SCD, DISCOVERY, Oregon SUDS, study, ICDs, gene
News | Sudden Cardiac Arrest| August 31, 2015
Medtronic plc announced first-of-its-kind findings from two independent studies that have identified a gene associated...
News | Heart Failure| August 28, 2015
August 28, 2015 — BioControl Medical said it has completed enrollment in its INOVATE-HF (INcrease Of VAgal TonE in He
BioSig Technologies, research agreement, UCLA, Pure EP System, EP lab, ventricular tachycardia model, VT
Technology | EP Lab| August 20, 2015
BioSig Technologies announced it has signed a sponsored research agreement with the regents of the University of...
Biotronik, BioCONTINUE study, CRT-D, defibrillator, cardiac resynchronization therapy device, heart failure, first replacement
News | Cardiac Resynchronization Therapy Devices (CRT)| August 17, 2015
Biotronik announced that the first patient has been enrolled in the BioCONTINUE clinical trial (BIOtronik study to...
CMS, additional participants, Bundled Payments for Care Improvement initiative, Medicare, eipsodes of care
News | Business| August 17, 2015
The Centers for Medicare & Medicaid Service (CMS) announced that over 2,100 healthcare facilities have agreed to...
Biotronik, BIOGUARD-MI Study, BioMonitor, cardiac arrhythmias, early detection, remote monitoring
News | Implantable Cardiac Monitor (ICM)| August 11, 2015
Biotronik announced the first enrollments in the BIO|GUARD-MI1 study. The study will investigate whether the early...
Boston Scientific, Preventice Solutions, equity investment, sales cooperation agreement, cardiac monitoring

BodyGuardian product family. Image courtesy of Preventice Solutions.

News | Remote Monitoring| August 11, 2015
Boston Scientific has become a significant shareholder and will become the exclusive worldwide sales and marketing...
Overlay Init